Clinical Trial Update: Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing FOLFOX plus cetuximab versus FOLFOXIRI plus bevacizumab, each with QL1706, as first-line therapy for left-sided metastatic colo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• FOLFOX
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)
• QL1706

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING